Rotarix reduces resource use and healthcare costs in USA

Rotarix reduces resource use and healthcare costs in USA PharmacoEconomics & Outcomes News 784, p26 - 12 Aug 2017 Rotarix reduces resource use and healthcare costs in USA GlaxoSmithKline’s (GSK’s) rotavirus vaccine, Rotarix [RIX 44414; RV1], reduces rotavirus (RV)- and diarrhoea-related resource use and healthcare costs in the US, according to findings of a GSK-funded study published in Vaccine. Data from Truven Commercial Claims and Encounters Databases were used to evaluate the public health impact of Rotarix vaccination in 225 587 commercially- insured children born between 2007 and 2010 and followed until up to five years of age. In total, 34 928 infants received complete vaccination (two doses), 8390 infants received incomplete vaccination (one dose), and 182 269 were unvaccinated. Compared with the unvaccinated cohort, the incidence of first episodes of rotavirus was significantly lower in the cohort who received complete vaccination (incidence rate ratio [IRR] 0.17; 95% CI 0.09, 0.30) or incomplete vaccination (IRR 0.19; 95% CI 0.06, 0.58). Rates of rotavirus-related inpatient, outpatient and emergency room (ER) visits, and diarrhoea-related inpatient and ER visits, were significantly lower in the cohort who received complete vaccination than in the unvaccinated cohort. Rates of rotavirus-related inpatient and ER visits were also significantly lower in the partially vaccinated cohort. The adjusted mean cost for first rotavirus episode was reduced by $11 511 per 1000 patients in the completely vaccinated cohort compared with the unvaccinated cohort, and the adjusted mean cost for first diarrhoea episode was reduced by $46 772 per 1000 patients. "Given the effectiveness of RV1 vaccination and RV vaccination in general, efforts should focus on improving RV vaccination rates which lag behind most pediatric vaccination rates and continue to fall below the Healthy People 2020 target of 80%," commented the authors. * 2012 US dollars Krishnarajah G, et al. Public health impact of Rotarix vaccination among commercially insured children in the United States. Vaccine : Aug 2017. Available from: URL: http://doi.org/10.1016/j.vaccine.2017.06.034 803263873 1173-5503/17/0784-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 12 Aug 2017 No. 784 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png PharmacoEconomics & Outcomes News Springer Journals

Rotarix reduces resource use and healthcare costs in USA

Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/rotarix-reduces-resource-use-and-healthcare-costs-in-usa-zQ1urTlyTl
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG
Subject
Medicine & Public Health; Pharmacoeconomics and Health Outcomes; Quality of Life Research; Health Economics; Public Health
ISSN
1173-5503
eISSN
1179-2043
D.O.I.
10.1007/s40274-017-4237-8
Publisher site
See Article on Publisher Site

Abstract

PharmacoEconomics & Outcomes News 784, p26 - 12 Aug 2017 Rotarix reduces resource use and healthcare costs in USA GlaxoSmithKline’s (GSK’s) rotavirus vaccine, Rotarix [RIX 44414; RV1], reduces rotavirus (RV)- and diarrhoea-related resource use and healthcare costs in the US, according to findings of a GSK-funded study published in Vaccine. Data from Truven Commercial Claims and Encounters Databases were used to evaluate the public health impact of Rotarix vaccination in 225 587 commercially- insured children born between 2007 and 2010 and followed until up to five years of age. In total, 34 928 infants received complete vaccination (two doses), 8390 infants received incomplete vaccination (one dose), and 182 269 were unvaccinated. Compared with the unvaccinated cohort, the incidence of first episodes of rotavirus was significantly lower in the cohort who received complete vaccination (incidence rate ratio [IRR] 0.17; 95% CI 0.09, 0.30) or incomplete vaccination (IRR 0.19; 95% CI 0.06, 0.58). Rates of rotavirus-related inpatient, outpatient and emergency room (ER) visits, and diarrhoea-related inpatient and ER visits, were significantly lower in the cohort who received complete vaccination than in the unvaccinated cohort. Rates of rotavirus-related inpatient and ER visits were also significantly lower in the partially vaccinated cohort. The adjusted mean cost for first rotavirus episode was reduced by $11 511 per 1000 patients in the completely vaccinated cohort compared with the unvaccinated cohort, and the adjusted mean cost for first diarrhoea episode was reduced by $46 772 per 1000 patients. "Given the effectiveness of RV1 vaccination and RV vaccination in general, efforts should focus on improving RV vaccination rates which lag behind most pediatric vaccination rates and continue to fall below the Healthy People 2020 target of 80%," commented the authors. * 2012 US dollars Krishnarajah G, et al. Public health impact of Rotarix vaccination among commercially insured children in the United States. Vaccine : Aug 2017. Available from: URL: http://doi.org/10.1016/j.vaccine.2017.06.034 803263873 1173-5503/17/0784-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 12 Aug 2017 No. 784

Journal

PharmacoEconomics & Outcomes NewsSpringer Journals

Published: Aug 12, 2017

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off